First two CAR-T cell medicines recommended for approval in the European Union

June 29, 2018 – The European Medicines Agency (EMA) has recommended the first two marketing authorisations for chimeric antigen receptors (CAR) T-cells medicines in the European Union (EU). Tisagenlecleucel and axicabtagene ciloleucel are advanced therapies for blood cancer. They belong to a new generation of personalised cancer immunotherapies that are based on collecting and modifying patients’ own immune cells to treat their cancer. Tisagenlecleucel … (leggi tutto)